S. Toovey

发表

Identification of a Vulnerable Group for Post-Acute Sequelae of SARS-CoV-2 (PASC): People with Autoimmune Diseases Recover More Slowly from COVID-19

N. Dreyer, D. Mohamed, N. Petruski-Ivleva, 2021, International journal of general medicine.

Travelers' knowledge, attitudes and practices on the prevention of infectious diseases: results from a study at Johannesburg International Airport.

S. Toovey, A. Jamieson, Michele Holloway, 2004, Journal of travel medicine.

Sulphasalazine and male infertility: reversibility and possible mechanism.

E. Hudson, S. Toovey, W. Hendry, 1981, Gut.

Sperm size in patients with inflammatory bowel disease on sulfasalazine therapy.

C. Doré, C. Sowter, E. Hudson, 1982, Fertility and sterility.

Influenza-associated central nervous system dysfunction: a literature review.

S. Toovey, 2008, Travel medicine and infectious disease.

Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study

S. Toovey, W. A. Blumentals, Anna Arreglado, 2012, BMC Musculoskeletal Disorders.

Body mass index and the incidence of influenza‐associated pneumonia in a UK primary care cohort

S. Toovey, W. A. Blumentals, Michael M. Peng, 2011, Influenza and other respiratory viruses.

Effect of artemisinins and amino alcohol partner antimalarials on mammalian sarcoendoplasmic reticulum calcium adenosine triphosphatase activity.

S. Krishna, Leyla Y. Bustamante, A. Uhlemann, 2008, Basic & clinical pharmacology & toxicology.

Special infectious disease risks of expatriates and long-term travelers in tropical countries. Part I: malaria.

S. Toovey, A. van Gompel, F. Moerman, 2007, Journal of travel medicine.

Reversible hearing loss in temporal association with chemoprophylactic mefloquine use.

S. Toovey, M. Wise, 2007, Travel medicine and infectious disease.

Special infectious disease risks of expatriates and long-term travelers in tropical countries. Part II: infections other than malaria.

S. Toovey, A. van Gompel, F. Moerman, 2007, Journal of travel medicine.

Travelling to Africa: health risks reviewed.

S. Toovey, 2006, Travel medicine and infectious disease.

Travelling to South Africa for the 2010 FIFA world cup.

P. Leggat, S. Toovey, M. Shaw, 2010, Travel medicine and infectious disease.

Are currently deployed artemisinins neurotoxic?

S. Toovey, 2006, Toxicology letters.

Cost-utility analysis of antiviral use under pandemic influenza using a novel approach – linking pharmacology, epidemiology and heath economics

R. Nelson, C. Rayner, C. Kirkpatrick, 2018, Epidemiology and Infection.

Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria

B. Darpo, B. Laurijssens, S. Toovey, 2015, British journal of clinical pharmacology.

Rolling back malaria: how well is Europe doing?

S. Toovey, A. Jamieson, 2003, Travel medicine and infectious disease.

Absence of adverse effects of oseltamivir on sleep: a double-blind, randomized study in healthy volunteers in Japan.

H. Kuwahara, N. Uchimura, C. Rayner, 2011, Basic & clinical pharmacology & toxicology.

Human infection with avian influenza virus, Pakistan, 2007.

N. Dreyer, S. Toovey, M. Zaman, 2011, Emerging infectious diseases.

Pretravel health advice for asplenic individuals.

S. Toovey, A. Jamieson, 2006, Journal of travel medicine.

Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case–control design

N. Dreyer, E. Brinkley, S. Toovey, 2022, medRxiv.

Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study.

D. Overbosch, K. Kain, J. Knobloch, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

H5N1 avian influenza in children.

N. Dreyer, O. Tsang, W. Hanshaoworakul, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

H 5 N 1 Avian In fl uenza in Children

N. Dreyer, O. Tsang, W. Hanshaoworakul, 2012 .

Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir

R. Gieschke, S. Sacks, C. Rayner, 2008, Drug safety.

Dengue fever and pregnancy - a review and comment.

S. Toovey, A. van Gompel, I. Carroll, 2007, Travel medicine and infectious disease.

Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines

Jonathan Berman, S. Toovey, G. Dow, 2018, Malaria Journal.

Post-Marketing Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir: An Updated Review

M. Britschgi, C. Rayner, Annette Koerner, 2012, Advances in Therapy.

Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review

S. Toovey, S. Duparc, S. Chalon, 2020, Malaria Journal.

Infections exotic and ectopic, and everyday practice.

S. Toovey, J. Zuckerman, 2011, Travel medicine and infectious disease.

Previously diagnosed influenza infections and the risk of developing epilepsy

S. Toovey, S. Jick, C. Meier, 2014, Epidemiology and Infection.

Recognizing true H5N1 infections in humans during confirmed outbreaks.

N. Dreyer, O. Tsang, W. Hanshaoworakul, 2014, Journal of infection in developing countries.

Human Infection with Avian Influenza Virus, Pakistan, 2007

N. Dreyer, S. Toovey, M. Zaman, 2011, Emerging Infectious Diseases.

COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine Effectiveness

N. Dreyer, E. Brinkley, S. Toovey, 2022, medRxiv.

The use of antiviral agents for the management of severe influenza

R. Ariano, S. Toovey, James R. Smith, 2010, Critical care medicine.

Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children

Bruno Reigner, Neil Parrott, Trevor N Johnson, 2018, British journal of clinical pharmacology.

Maternal immune activation and abnormal brain development across CNS disorders

Irene Knuesel, M. Britschgi, J. Hellings, 2014, Nature Reviews Neurology.

Falciparum malaria presenting with pruritic rashes.

S. Toovey, A. Jamieson, C. Hatz, 2004, Travel medicine and infectious disease.

Malaria chemoprophylaxis advice: survey of South African community pharmacists' knowledge and practices.

S. Toovey, 2006, Journal of travel medicine.

The role of standby emergency medication for falciparum malaria: current opinion.

R. Price, S. Toovey, C. Hatz, 2004, Travel medicine and infectious disease.

Pharmacokinetic-Pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies

C. Rayner, S. Toovey, S. Bhavnani, 2013, Antimicrobial Agents and Chemotherapy.

Comparison of antiviral resistance across acute and chronic viral infections

J. Wu, S. Toovey, J. Devincenzo, 2018, Antiviral research.

Preventing rabies with the Verorab vaccine: 1985-2005 Twenty years of clinical experience.

S. Toovey, 2007, Travel medicine and infectious disease.

Knowledge, attitudes and practices of expatriates towards malaria chemoprophylaxis and personal protection measures on a mine in Mali.

S. Toovey, S. Jute, 2007, Travel medicine and infectious disease.

Tafenoquine for malaria prophylaxis in adults: An integrated safety analysis.

S. Toovey, Bryan L. Smith, G. Dow, 2017, Travel medicine and infectious disease.

Co-artemether has been used in ambulatory treatment of falciparum malaria

S. Toovey, A. Jamieson, 2002, BMJ : British Medical Journal.

Mefloquine neurotoxicity: a literature review.

S. Toovey, 2009, Travel medicine and infectious disease.

Tafenoquine is not neurotoxic following supertherapeutic dosing in rats.

S. Toovey, Bryan L. Smith, G. Dow, 2017, Travel medicine and infectious disease.

Malaria chemoprophylaxis regimens: a descriptive drug utilization study.

P. Schlagenhauf, S. Toovey, S. Jick, 2014, Travel medicine and infectious disease.

Effects of weight, age, and time on artemether-lumefantrine associated ototoxicity and evidence of irreversibility.

S. Toovey, 2006, Travel medicine and infectious disease.

Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether.

S. Toovey, A. Jamieson, 2004, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Haemoglobinuria in a case of Falciparum malaria treated with co-artemether.

S. Toovey, A. Jamieson, G. Nettleton, 2003, Travel medicine and infectious disease.

Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines

Jonathan Berman, S. Toovey, G. Dow, 2018, Malaria Journal.

Schistosomicidal activity of the antimalarial drug, mefloquine, in Schistosoma mansoni-infected mice.

Jozef Vercruysse, Jean-Pierre Timmermans, J. Timmermans, 2008, Travel medicine and infectious disease.

Possible cures for clinical rabies: Are they already on the pharmacy shelf?

S. Toovey, 2016, Travel medicine and infectious disease.

Zebra bite to a South African tourist.

S. Toovey, A. Jamieson, Zacharias Annandale, 2006, Journal of travel medicine.

Advising the pregnant and

S. Toovey, 2005 .

A case of dura mater graft-associated Creutzfeldt-Jakob disease in South Africa.

S. Toovey, R. Hewlett, M. Britz, 2006, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

A new inactivated Japanese encephalitis vaccine for adult travelers.

S. Toovey, 2009, Travel medicine and infectious disease.

Gideon database.

S. Toovey, 2010, Travel medicine and infectious disease.

Meeting Report: Risk Assessment of Tamiflu Use Under Pandemic Conditions

Jürg Oliver Straub, Mark Crane, Chris Watts, 2008, Environmental health perspectives.

Influenza infections and risk of Alzheimer’s disease

S. Toovey, S. Jick, C. Meier, 2016, Brain, Behavior, and Immunity.

Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellers.

P. Schlagenhauf, K. Nieforth, S. Toovey, 2014, Travel medicine and infectious disease.

Prevention of influenza among travellers attending at a UK travel clinic: beliefs and perceptions. A cross‐sectional study

C. Masuet-Aumatell, S. Toovey, J. Zuckerman, 2012, Influenza and other respiratory viruses.

Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry.

N. Dreyer, A. Oner, R. Coker, 2010, The Journal of infectious diseases.

Determinants of antiviral effectiveness in influenza virus A subtype H5N1.

N. Dreyer, O. Tsang, W. Hanshaoworakul, 2012, The Journal of infectious diseases.

Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study

E. Winzeler, D. Fidock, M. Phillips, 2018, The Lancet. Infectious diseases.

Drug resistant pathogens and travel: No road map but a new initiative from Travel Medicine and Infectious Disease.

A. Rodríguez-Morales, P. Schlagenhauf, P. Gautret, 2016, Travel medicine and infectious disease.

Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics

Nathorn Chaiyakunapruk, Huey Yi Chong, Richard E Nelson, 2017, British journal of clinical pharmacology.

The risk of new onset depression in association with influenza – A population-based observational study

S. Toovey, S. Jick, C. Meier, 2016, Brain, Behavior, and Immunity.

Reply to comment on: Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether

S. Toovey, 2005 .

Response to: artemisinin derivatives: toxic for laboratory animals, safe for humans?

S. Toovey, A. Jamieson, 2004, Toxicology letters.

Successful co-artemether (artemether-lumefantrine) clearance of falciparum malaria in a patient with severe cholera in Mozambique.

S. Toovey, A. Jamieson, G. Nettleton, 2003, Travel medicine and infectious disease.

Parkinson’s disease or Parkinson symptoms following seasonal influenza

S. Toovey, S. Jick, C. Meier, 2011, Influenza and other respiratory viruses.

Safety of artemisinin antimalarials.

S. Toovey, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cognitive and other neuropsychiatric symptoms in COVID-19: analysis of person-generated longitudinal health data from a community-based registry

N. Dreyer, E. Brinkley, S. Toovey, 2023, BMJ open.

How frequent are acute reactions to COVID-19 vaccination and who is at risk?

N. Dreyer, E. Brinkley, S. Toovey, 2021, Vaccine.

Self-reported symptoms from exposure to Covid-19 provide support to clinical diagnosis, triage and prognosis: An exploratory analysis

N. Dreyer, N. Petruski-Ivleva, E. Brinkley, 2020, Travel Medicine and Infectious Disease.

Artesunate versus quinine for severe falciparum malaria

S. Toovey, 2006, The Lancet.

The Authorsʼ Reply

S. Toovey, 2012 .

Effectiveness of co-artemether in an unsupervised outpatient setting for the treatment of falciparum malaria.

S. Toovey, 2008, Travel medicine and infectious disease.

Previously diagnosed influenza infections and the risk of developing epilepsy

S. Toovey, S. Jick, J. Wilson, 2014, Epidemiology and Infection.

Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir

R. Gieschke, S. Sacks, C. Rayner, 2008, Drug safety.

Sulphasalazine and male infertility: reversibility and possible mechanism.

S. Toovey, Elizabeth Hudson, W. Hendry, 1981, Gut.

A case-control auditory evaluation of patients treated with artemether-lumefantrine.

S. Toovey, 2006, The American journal of tropical medicine and hygiene.

Comment on: no hearing loss associated with the use of artemether-lumefantrine to treat experimental human malaria.

S. Toovey, 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Safety and efficacy of AK0529 in respiratory syncytial virus‐infected infant patients: A phase 2 proof‐of‐concept trial

Yhu-Chering Huang, S. Toovey, C. Chieng, 2023, Influenza and other respiratory viruses.